BioCryst Pharmaceuticals, Inc. (BCRX) - What Are Brokerages Saying About This Stock?

Key Points

• Analyst consensus is moderately bullish: Twelve firms rate BioCryst Pharmaceuticals “Moderate Buy,” with seven buys, four holds and one sell. The average 12-month price target is $20.50.
• Recent recommendations were mixed, including Cantor Fitzgerald raising its target to $29 and RBC cutting its rating to “sector perform” with an $11 target; Weiss Ratings downgraded the stock to “sell.”
• BioCryst beat quarterly earnings and revenue estimates, reporting $0.30 EPS and $218.25 million in revenue, up 33.6% year over year. Institutional investors own approximately 85.88% of the shares.

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the twelve ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $20.50.

A number of brokerages have recently weighed in on BCRX. Royal Bank Of Canada lowered shares of BioCryst Pharmaceuticals from an "outperform" rating to a "sector perform" rating and dropped their price objective for the company from $13.00 to $11.00 in a report on Thursday, September 10th. Needham & Company LLC reaffirmed a "buy" rating and set a $16.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 8th. Cantor Fitzgerald boosted their price target on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an "overweight" rating in a research note on Tuesday, June 30th. Wedbush cut their price objective on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. Finally, Weiss Ratings cut BioCryst Pharmaceuticals from a "hold (c)" rating to a "sell (d-)" rating in a research note on Tuesday, September 22nd.

BioCryst Pharmaceuticals Trading Up 3.1%

NASDAQ BCRX opened at $8.55 on Friday. The firm's fifty day simple moving average is $9.12 and its two-hundred day simple moving average is $9.20. The firm has a market capitalization of $2.18 billion, a P/E ratio of -5.70 and a beta of 0.55. BioCryst Pharmaceuticals has a 12-month low of $6.00 and a 12-month high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.15 by $0.15. The firm had revenue of $218.25 million during the quarter, compared to analyst estimates of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. BioCryst Pharmaceuticals's revenue was up 33.6% on a year-over-year basis. During the same period last year, the firm posted $0.15 EPS. As a group, sell-side analysts predict that BioCryst Pharmaceuticals will post -2.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently bought and sold shares of BCRX. WINTON GROUP Ltd lifted its stake in BioCryst Pharmaceuticals by 380.3% during the 2nd quarter. WINTON GROUP Ltd now owns 255,600 shares of the biotechnology company's stock valued at $2,556,000 after acquiring an additional 202,384 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the second quarter worth $108,000. IFP Advisors Inc increased its stake in shares of BioCryst Pharmaceuticals by 2,515.3% in the second quarter. IFP Advisors Inc now owns 3,243 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 3,119 shares during the period. Squarepoint Ops LLC raised its holdings in shares of BioCryst Pharmaceuticals by 339.4% during the second quarter. Squarepoint Ops LLC now owns 174,714 shares of the biotechnology company's stock worth $1,747,000 after purchasing an additional 134,949 shares during the last quarter. Finally, Allworth Financial LP raised its holdings in shares of BioCryst Pharmaceuticals by 984.3% during the second quarter. Allworth Financial LP now owns 5,172 shares of the biotechnology company's stock worth $52,000 after purchasing an additional 4,695 shares during the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes oral medicines for rare diseases. The company focuses on small-molecule therapies designed to address diseases with significant unmet medical needs, including hereditary angioedema and complement-mediated disorders.

BioCryst's primary commercial product is Orladeyo (berotralstat), an oral plasma kallikrein inhibitor used to prevent attacks of hereditary angioedema in adults and pediatric patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.